Fragasso Financial Advisors Inc Lowers Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Fragasso Financial Advisors Inc trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 33.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,153 shares of the company's stock after selling 4,700 shares during the period. Fragasso Financial Advisors Inc's holdings in Hims & Hers Health were worth $270,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the period. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Hims & Hers Health by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Melissa Baird sold 33,333 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the sale, the chief operating officer now directly owns 805,083 shares of the company's stock, valued at $20,755,039.74. The trade was a 3.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $52.98, for a total transaction of $613,561.38. Following the sale, the chief financial officer now directly owns 39,153 shares of the company's stock, valued at $2,074,325.94. This represents a 22.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 617,367 shares of company stock valued at $25,227,888. Company insiders own 13.71% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Citigroup restated a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Leerink Partners raised their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, Bank of America raised their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Stock Down 1.7%

Shares of Hims & Hers Health stock traded down $0.95 during trading on Wednesday, hitting $53.78. 60,326,153 shares of the company were exchanged, compared to its average volume of 20,386,777. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a market capitalization of $12.04 billion, a price-to-earnings ratio of 122.23 and a beta of 1.84. The firm has a 50 day moving average price of $40.77 and a 200 day moving average price of $36.56.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's quarterly revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS. Analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.